<DOC>
	<DOCNO>NCT01846507</DOCNO>
	<brief_summary>This study learn drug call Tranexamic acid ( TA ) , otherwise know Lysteda , whether drug decrease menstrual blood loss young woman lead increase quality life . Menorrhagia young woman bleed disorder typically treat combination treatment include hormonal contraceptive . However , barrier hormonal contraception use young adolescent . Tranexamic acid take orally first 5 day menstrual bleeding . The purpose study include : To test safety efficacy Lysteda adolescent female . To learn well Lysteda work decrease menstrual blood loss . To see parent child participate study think drug improve quality life . Lysteda approve Food Drug Administration use patient &gt; 18 year age young patient .</brief_summary>
	<brief_title>Tranexamic Acid Adolescents With Heavy Menstrual Bleeding</brief_title>
	<detailed_description>This multi-center ( 5 site ) open-label , single-arm , efficacy study Lysteda treatment adolescent female ( 10-19 year age ) heavy menstrual bleeding ( HMB ) . Each subject receive oral Lysteda 1.3 gram three time daily first five day menses . Subjects monitor course four menstrual cycle ( 1 pre-treatment cycle 3 treatment cycle ) . During cycle , assessment menstrual bleeding perform use Menorrhagia Impact Questionnaire ( MIQ ) Pictorial Blood Assessment Chart ( PBAC ) . The study begin currently fund pilot study assess efficacy Lysteda 32 patient follow study completion .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>1 . Menstruating females 1019 year age 2 . Nonsmoker 3 . Physician patient agree initiate Lysteda 4 . Diagnosis HMB base medical judgment principal site investigator 5 . Subjects must report menstrual period occur within 2160 day start one period start next menstrual period 6 . Negative pregnancy test 7 . Informed consent obtain sign 8 . Informed assent obtain sign 9 . Understanding study procedure 10 . Ability comply study procedure entire length study 11 . Subjects either sexually inactive ( abstinent ) agree use barrier method spermicide event sexual activity throughout study period 1 . Active thromboembolic disease , history thromboembolic disease ( include retinal vein artery occlusion ) , know inherited thrombophilia , family history thrombosis first degree relative 2 . Subject severe medical psychiatric illness , opinion Investigator , would affect subject safety compliance 3 . Clinical evidence severe bleed disorder . Patients mild bleed disorder type 1 von Willebrand disease , mild platelet function defect platelet storage pool release defect , patient bleed due Ehlers Danlos syndrome WILL eligible participate study . 4 . Pregnancy within past 6 month and/or breastfeed 5 . Use hormonal contraception ( estrogen progestin ) within 3 month study entry , anticipate need initiate estrogencontaining hormonal contraception study period 6 . Use systemic steroid within 1 month study entry 7 . History subarachnoid hemorrhage 8 . History Hepatitis B , C , HIV 9 . Baseline creatinine &gt; 20 % upper limit normal age 10 . Severe anemia ( hemoglobin &lt; 8 g/dL ) 11 . Systolic blood pressure &lt; 85 diastolic blood pressure &lt; 55 12 . Heart rate &lt; 50 time screen 13 . Use intranasal DDAVP menses permit , patient history use DDAVP consistently â‰¥3 menstrual cycle prior study enrollment , change menstrual blood loss due addition Lysteda assess . Use onetime DDAVP DDAVP/Stimate challenge also permit study period , use DDAVP event severe epistaxis , trauma , surgical procedure study period .</criteria>
	<gender>Female</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Heavy Menstrual Bleeding</keyword>
	<keyword>HMB</keyword>
	<keyword>Lysteda</keyword>
</DOC>